Breaking Barriers to Care: Retinal Disease in At-Risk Populations

Supported by an unrestricted educational grant from Regeneron Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Discuss how demographics and socioeconomics impacts patient awareness of the ocular complications of diabetes
• Explain the efficacy of current treatment options in specific populations
• Develop individualized plans for patients with diabetic eye disease who may be at higher risk for progression due to nonadherence
• Apply case study examples to clinical settings

Accreditation and Designation Statement

Provided by Evolve Medical Education 

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

 ETHICS  
This course has been designated for 1.0 credit(s) of education in medical ethics and/or professional responsibility.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Ankoor Shah, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Novartis, Ocular Therapeutix.

Nancy Holekamp, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Apellis, Bayer, Lineage Cell Therapeutics, Clearside Biosciences, Gemini, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva,  and Regeneron Pharmaceuticals. Grant/Research Support: Genentech, Gemini, Gyroscope, Notal Vision. Speaker's Bureau: Allergan, Genentech, Novartis, Regeneron Pharmaceuticals, and Spark Therapeutics. Shareholder: Katalyst Surgical.

John W. Kitchens, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera, Allergan, Bayer, Carl Zeiss Meditec, Genentech, Kodiak Sciences, and Regeneron Pharmaceuticals. Grant/Research Support: Kodiak Sciences. Speaker's Bureau: Bayer, Genentech, and Regeneron Pharmaceuticals.

Yoshihiro Yonekawa, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Alimera, Allergan, and Genentech. 

The Evolve staff and planners have no financial relationships with commercial interests. Michelle Dalton, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Regeneron Pharmaceuticals